Follistatin

Research Overview

Follistatin's primary biochemical function as a high-affinity binding and neutralising protein for TGF-β ligands has positioned it as a key research tool at the intersection of muscle biology, reproductive endocrinology, and growth factor signalling. In muscle biology research, its capacity to antagonise myostatin — the principal negative regulator of skeletal muscle mass — has been studied extensively using transgenic and knockout preclinical models; follistatin-overexpressing mice exhibit dramatic increases in skeletal muscle mass analogous to those seen in myostatin-null animals. Separately, follistatin's role as an activin antagonist in the anterior pituitary provides a mechanistic research tool for FSH secretion regulation studies. Supplied exclusively for laboratory and research use.

Myostatin (GDF-8), a member of the TGF-β superfamily, acts through ActRIIB/ALK4 receptor complexes to suppress skeletal muscle hypertrophy and regeneration via SMAD2/3 signalling. Follistatin disrupts this pathway by binding myostatin with sub-nanomolar affinity, preventing receptor engagement and downstream SMAD activation. Preclinical evidence from transgenic mouse models overexpressing follistatin demonstrates two- to three-fold increases in skeletal muscle mass, supporting its utility as a research probe for TGF-β ligand-dependent muscle growth signalling. In reproductive biology research, follistatin's antagonism of activin A and B has been studied in relation to FSH feedback regulation and folliculogenesis in gonadal cell models. All outcomes referenced pertain to preclinical models and do not constitute evidence of clinical efficacy or safety in humans.